CIK 0001281895
- Non-accelerated filer
- Smaller reporting company
ROCKET PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RCKT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 646-440-9100
- Business address
- 350 FIFTH AVENUE, SUITE 7530, NEW YORK, NY, 10118
- Former names
- INOTEK PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $411,605
- in 5 filings
Net −$411,605. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 48 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-03-31 | Shah Gaurav CEO | Exercise or conversion · Stock Option (Right to Buy) | −75,880 | 0 | ||
| 2021-03-30 | Shah Gaurav CEO | Shares withheld for taxes | −19,984 | $41.80 | $835K | 614,092 |
| 2021-03-30 | Shah Gaurav CEO | Shares withheld for taxes | −8,667 | $42.80 | $371K | 594,108 |
| 2021-03-30 | Shah Gaurav CEO | Shares withheld for taxes | −48,732 | $43.86 | $2.1M | 545,376 |
| 2021-03-30 | Shah Gaurav CEO | Shares withheld for taxes | −8,505 | $44.34 | $377K | 536,871 |
| 2021-03-24 | RTW INVESTMENTS, LP Director | Other disposition | −1,344,925 | 16,185,119 | ||
| 2021-03-24 | Patel Kinnari Chief Operating Officer | Exercise or conversion | +55,869 | $1.21 | $68K | 150,846 |
| 2021-03-24 | Patel Kinnari Chief Operating Officer | Exercise or conversion | +38,093 | $1.69 | $64K | 188,939 |
| 2021-03-24 | Patel Kinnari Chief Operating Officer | Exercise or conversion · Stock Option (Right to Buy) | −55,869 | 0 | ||
| 2021-03-24 | Patel Kinnari Chief Operating Officer | Exercise or conversion · Stock Option (Right to Buy) | −38,093 | 0 | ||
| 2021-02-04 | Patel Kinnari Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +120,000 | 120,000 | ||
| 2021-02-04 | Militello John | Returned to the company · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2021-02-04 | Shah Gaurav President & CEO | Grant or award · Stock Option (Right to Buy) | +185,000 | 185,000 | ||
| 2021-02-04 | Schwartz Jonathan David Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2021-02-01 | Schwartz Jonathan David Chief Medical Officer | Exercise or conversion | +11,428 | $1.69 | $19K | 11,428 |
| 2021-02-01 | Schwartz Jonathan David Chief Medical Officer | Exercise or conversion | +213,101 | $1.21 | $258K | 224,529 |
| 2021-02-01 | Schwartz Jonathan David Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −11,428 | 0 | ||
| 2021-01-04 | Garcia-Parada Carlos Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2020-12-28 | Patel Kinnari Chief Operating Officer | Sale | −11,334 | $56.51 | $641K | 100,404 |
| 2020-12-28 | Patel Kinnari Chief Operating Officer | Sale | −5,427 | $57.17 | $310K | 94,977 |
Page 23 of 27 · 538 trades